Addus HomeCare's (ADUS) "Market Outperform" Rating Reiterated at JMP Securities

Addus HomeCare (NASDAQ:ADUS - Get Free Report)'s stock had its "market outperform" rating reiterated by equities research analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They presently have a $150.00 target price on the stock. JMP Securities' price objective would suggest a potential upside of 54.19% from the stock's current price.

A number of other equities analysts also recently issued reports on the stock. Macquarie reiterated an "outperform" rating and issued a $129.00 price target on shares of Addus HomeCare in a report on Thursday, February 27th. StockNews.com cut Addus HomeCare from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Stephens reiterated an "overweight" rating and set a $142.00 price objective on shares of Addus HomeCare in a research note on Wednesday, March 12th. Finally, Oppenheimer increased their target price on Addus HomeCare from $145.00 to $150.00 and gave the company an "outperform" rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Addus HomeCare currently has a consensus rating of "Moderate Buy" and an average price target of $132.78.

Addus HomeCare Stock Down 3.9 %

Shares of ADUS stock opened at $97.28 on Tuesday. The business has a 50-day simple moving average of $99.11 and a 200-day simple moving average of $116.78. Addus HomeCare has a 52-week low of $87.88 and a 52-week high of $136.72. The stock has a market cap of $1.77 billion, a PE ratio of 22.26, a price-to-earnings-growth ratio of 1.41 and a beta of 0.93.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.35 by ($0.09). The company had revenue of $297.14 million for the quarter, compared to analyst estimates of $291.04 million. Addus HomeCare had a return on equity of 9.62% and a net margin of 6.50%. Sell-side analysts anticipate that Addus HomeCare will post 4.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Addus HomeCare

Several institutional investors and hedge funds have recently bought and sold shares of the business. Natixis increased its holdings in Addus HomeCare by 111.9% in the fourth quarter. Natixis now owns 250 shares of the company's stock worth $31,000 after buying an additional 132 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Addus HomeCare by 324.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 280 shares of the company's stock worth $35,000 after purchasing an additional 214 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Addus HomeCare by 38.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 531 shares of the company's stock valued at $67,000 after acquiring an additional 148 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Addus HomeCare in the fourth quarter valued at approximately $77,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Addus HomeCare during the 4th quarter worth $86,000. Hedge funds and other institutional investors own 95.35% of the company's stock.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.